MEDSCI (02415) Reports Interim Results with Net Profit of RMB 13.239 Million, Up 5238.3% YoY
Stock News
Aug 29
MEDSCI (02415) announced its interim results for 2025, reporting revenue of RMB 125 million, representing a year-on-year increase of 13.2%. Net profit reached RMB 13.239 million, surging 5238.3% compared to the same period last year. Basic earnings per share stood at 2.45 cents, with the company proposing an interim dividend of HK 1.1 cents per share. During the period, total revenue grew year-on-year, primarily driven by the recovery of the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies toward evidence-driven marketing models, which boosted demand for precision omnichannel marketing solutions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.